Comparing of Assembly Biosciences Inc. (ASMB) and Cyanotech Corporation (NASDAQ:CYAN)

Both Assembly Biosciences Inc. (NASDAQ:ASMB) and Cyanotech Corporation (NASDAQ:CYAN) are Biotechnology companies, competing one another. We will compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Assembly Biosciences Inc. 14.38M 40.50 67.60M -3.58 0.00
Cyanotech Corporation 32.24M 0.56 3.18M -0.21 0.00

In table 1 we can see Assembly Biosciences Inc. and Cyanotech Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Assembly Biosciences Inc. and Cyanotech Corporation’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Assembly Biosciences Inc. -470.10% -50.6% -36%
Cyanotech Corporation -9.86% -13.5% -7.9%

Volatility and Risk

Assembly Biosciences Inc.’s volatility measures that it’s 39.00% more volatile than Standard and Poor’s 500 due to its 1.39 beta. Competitively, Cyanotech Corporation is 33.00% less volatile than Standard and Poor’s 500, because of the 0.67 beta.

Liquidity

16.4 and 16.4 are the respective Current Ratio and a Quick Ratio of Assembly Biosciences Inc. Its rival Cyanotech Corporation’s Current and Quick Ratios are 1.8 and 0.4 respectively. Assembly Biosciences Inc. has a better chance of clearing its pay short and long-term debts than Cyanotech Corporation.

Analyst Ratings

Assembly Biosciences Inc. and Cyanotech Corporation Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Assembly Biosciences Inc. 0 0 1 3.00
Cyanotech Corporation 0 0 0 0.00

Assembly Biosciences Inc. has a 83.57% upside potential and an average price target of $42.

Institutional and Insider Ownership

Assembly Biosciences Inc. and Cyanotech Corporation has shares owned by institutional investors as follows: 86.3% and 13.8%. 5.5% are Assembly Biosciences Inc.’s share owned by insiders. Comparatively, insiders own roughly 19.1% of Cyanotech Corporation’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Assembly Biosciences Inc. -2.56% 9.22% -30.72% -42.6% -41.43% -44.49%
Cyanotech Corporation -5.56% 6.06% -3.37% -12.73% -17.93% -11.82%

For the past year Cyanotech Corporation has weaker performance than Assembly Biosciences Inc.

Summary

On 8 of the 11 factors Cyanotech Corporation beats Assembly Biosciences Inc.

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead product candidate from the platform is AB-M101 that has been completed Phase Ia clinical trial to treat clostridium difficile infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition market worldwide. The companyÂ’s products include Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids; and Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the bodyÂ’s natural inflammatory response, enhance skin, and support eye and joint health. Cyanotech Corporation sells its products in bulk quantities to manufacturers, formulators, and distributors in the health foods and nutritional supplements markets; and as packaged consumer products to distributors, retailers, and direct consumers. The company also sells its products online at nutrex-hawaii.com. Cyanotech Corporation was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.